[Multicenter study of the clinical efficacy and tolerance of roxithromicin compared to doxycycline in lower respiratory infections].
In a double-blind, randomised investigation in 305 in-patients, roxithromycin and doxycycline were compared in two groups of patients with low respiratory tract infections. Three hundred cases were analyzable for safety and 276 for clinical efficacy. Mean duration of treatment was 9 days in both groups. Clinical effectiveness was 83% (112/135) for roxithromycin (150 mg bd) and 84% (118/141) for doxycycline (200 mg once daily), the difference not being statistically significant. A 90% clinical response rate was obtained with roxithromycin in pneumoniae. Safety and tolerance were good and comparable in both groups.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy; D011897:Random Allocation; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D007933:Leucomycins; D004318:Doxycycline
Etude multicentrique de l'efficacité clinique et de la tolérance de la roxithromycine comparée à la doxycycline dans les infections respiratoires basses.